Literature DB >> 15724016

Clinical features of multiple cutaneous and uterine leiomyomatosis: an underdiagnosed tumor syndrome.

N Afrina Alam1, Ella Barclay, Andrew J Rowan, Jonathan P Tyrer, Eduardo Calonje, Sanjiv Manek, David Kelsell, Irene Leigh, Simon Olpin, Ian P M Tomlinson.   

Abstract

OBJECTIVE: To investigate the clinical features of the multiple cutaneous and uterine leiomyomatosis (MCUL) syndrome, including the hereditary leiomyomatosis and renal cell cancer syndrome.
DESIGN: A case series of patients with multiple skin leiomyomas solicited via a circular letter to dermatologists.
SETTING: Research institute. PATIENTS: A total of 108 affected individuals, including 46 probands and 62 affected relatives. MAIN OUTCOME MEASURES: The proportion of probands with underlying fumarate hydratase (FH) mutations, the penetrance of FH mutations, and clinicopathologic features of MCUL.
RESULTS: Forty-one (89%) of 46 probands with multiple skin leiomyomas had evidence of germline FH mutations, which were highly penetrant. All 26 male mutation carriers had skin leiomyomas. Of 67 women with FH mutations, 46 (69%) had both skin and uterine leiomyomas; 10 (15%) had only skin leiomyomas; 5 (7%) had only uterine leiomyomas; and 6 (9%) were clinically unaffected. Patients presented with skin leiomyomas at a mean age of 24 years and had a mean of 25 lesions. Forty-one individuals (89%) reported painful lesions, particularly in response to cold or trauma. Fibroids were histologically unremarkable, highly symptomatic, and associated with a high risk of early hysterectomy. One individual had a very aggressive collecting duct renal cancer. The G354R FH mutation predisposed patients to uterine fibroids without skin leiomyomas (P = .03). Many patients with skin leiomyomas had not previously presented for medical attention. Fibroids were rarely recognized as cases of MCUL.
CONCLUSIONS: Highly penetrant FH mutations underlie MCUL. Increased clinical awareness is important because of the associated risk of severe uterine fibroids and, in some cases, aggressive renal cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15724016     DOI: 10.1001/archderm.141.2.199

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  49 in total

1.  Increased risk of cancer in patients with fumarate hydratase germline mutation.

Authors:  H J Lehtonen; M Kiuru; S K Ylisaukko-Oja; R Salovaara; R Herva; P A Koivisto; O Vierimaa; K Aittomäki; E Pukkala; V Launonen; L A Aaltonen
Journal:  J Med Genet       Date:  2005-09-09       Impact factor: 6.318

2.  Gene expression analysis in peripheral blood cells of patients with hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC): identification of NRF2 pathway activation.

Authors:  Carolina Arenas Valencia; Liliana Lopez Kleine; Andres M Pinzon Velasco; Andrea Y Cardona Barreto; Clara E Arteaga Diaz
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

3.  Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm Meeting.

Authors:  Neal Bhatia; Andrew Blauvelt; Marc Brown; Whitney High; Craig T Leonardi; Ted Rosen; Linda Stein Gold; Eggert Stockfleth; Bruce Strober; Neil A Swanson; George Martin
Journal:  J Clin Aesthet Dermatol       Date:  2014-07

4.  The second genome: Effects of the mitochondrial genome on cancer progression.

Authors:  Adam D Scheid; Thomas C Beadnell; Danny R Welch
Journal:  Adv Cancer Res       Date:  2019-02-27       Impact factor: 6.242

5.  A retrospective review of 48 individuals, including 12 families, molecularly diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC).

Authors:  Priya T Bhola; Cathy Gilpin; Amanda Smith; Gail E Graham
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

Review 6.  Hereditary kidney cancer syndromes.

Authors:  Naomi B Haas; Katherine L Nathanson
Journal:  Adv Chronic Kidney Dis       Date:  2014-01       Impact factor: 3.620

7.  Hereditary leiomyomatosis and renal cell cancer syndrome: identification and clinical characterization of a novel mutation in the FH gene in a Colombian family.

Authors:  Carolina Arenas Valencia; Martha Lucia Rodríguez López; Andrea Yimena Cardona Barreto; Edgar Garavito Rodríguez; Clara Eugenia Arteaga Díaz
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

8.  Unilateral multi-segmental leiomyomas: a report of rare case.

Authors:  Chandramohan Kudligi; Binod K Khaitan; Pradeep Vittal Bhagwat; Dinesh Prasad Asati
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

Review 9.  10 rare tumors that warrant a genetics referral.

Authors:  Kimberly C Banks; Jessica J Moline; Monica L Marvin; Anna C Newlin; Kristen J Vogel
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

10.  No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome.

Authors:  Pia Vahteristo; Taru A Koski; Laura Näätsaari; Maija Kiuru; Auli Karhu; Riitta Herva; Satu-Leena Sallinen; Outi Vierimaa; Erik Björck; Stéphane Richard; Betty Gardie; Didier Bessis; Emmanuel Van Glabeke; Ignacio Blanco; Richard Houlston; Leigha Senter; Marja Hietala; Kristiina Aittomäki; Lauri A Aaltonen; Virpi Launonen; Rainer Lehtonen
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.